News and Trends 25 Jan 2018 British Biotech Treats First Phase III Patient in its Critical Limb Ischemia Trial Rexgenero has treated the first patient in a Phase III trial investigating REX-001, the biotech’s cell therapy for critical limb ischemia. Rexgenero is a biotech working on regenerative medicine techniques to treat critical limb ischemia (CLI). The condition is characterized by blocked arteries in the lower limbs that can force doctors to amputate. The company has […] January 25, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2018 Researchers Take Aim at Pancreatic Cancer with a Modified Flu Virus In an early study at Queen Mary University in London, a modified flu virus has been able to block the growth of pancreatic cancer. For the first time, researchers at Queen Mary University, London, have shown that pancreatic cancer can be targeted using a modified flu virus. During a study, published in Molecular Cancer Therapeutics, […] January 25, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jan 2018 No More Mosquito Bites? Targeting These Genes Could Prevent Future Outbreaks! Researchers may have found a way to stop the female mosquitoes from biting you, which could help to prevent the spread of diseases like malaria. Scientists at the University of Birmingham in the UK and the University of Notre Dame in Paris, along with collaborators in the US, have identified 902 genes specific to blood-feeding mosquitoes […] January 22, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2018 Meet the 10 Promising Synbio Startups in RebelBio’s London Cohort Irish accelerator RebelBio has launched its latest cohort of startups that will receive its support during a 3-month program at Imperial College London. RebelBio is a startup accelerator that helps entrepreneurs to build technology associated with the life sciences field. It offers seed funding, lab space, mentorship, and a community of successful and diverse founders […] January 18, 2018 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2018 Oxford Firm Recruits Two Partners to Build Drug Discovery AI e-Therapeutics has teamed up with AI experts Intellegens and Biorelate to improve its technology for computer-based drug discovery. Based in Oxford, e-Therapeutics has the mission of reducing the time and money it costs to develop new drugs with the help of artificial intelligence. Its platform can explore large amounts of public and private databases to […] January 16, 2018 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2018 Young Oxford Biotech Raises €22.5M to Develop a Universal Flu Vaccine Vaccitech has closed a Series A fundraising that will support clinical trials with its vaccine technology against influenza and prostate cancer. Spun out from Oxford University in 2016, Vaccitech has now closed its Series A fundraising round. Amounting to a total of £20M (€22.5M), the round was co-led by GV, Oxford Sciences Innovation and Sequoia China, and joined […] January 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2018 British Biotech’s Technology is Taken by Pharma to Fight Alzheimer’s Having developed multispecific antibodies with F-star, Denali Therapeutics has joined forces with Takeda Pharmaceuticals to commercialize Alzheimer’s drugs using the technology. F-star’s bispecific antibody technology has received validation in the form of two pharma companies using it for the development of new drugs for neurodegenerative diseases. San Francisco-based Denali Therapeutics and Japanese company Takeda will collaborate on […] January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2018 The FDA Gives AstraZeneca’s Breast Cancer Drug the Go-Ahead The UK big pharma company’s Lynparza will be for women with advanced breast cancer that is specifically caused by mutations in the BRCA gene. Global pharma giant AstraZeneca focuses on the development of drugs for cancer, cardiovascular and respiratory diseases. The company, which is working on a number of small molecules and biologics for a […] January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2018 This Collaboration Will Develop a New Epilepsy Gene Therapy for In-Need Patients CombiGene and the Cell and Gene Therapy Catapult have struck a deal that will move the biotech’s epilepsy therapy towards the clinic. Swedish biotech CombiGene has combined neuroscience and advances in gene delivery to pioneer and new therapy for epilepsy that has brought down the number of seizures in preclinical studies. The company has joined forces […] January 12, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2018 These Biomaterials Could Help to Make Stem Cell Therapies a Reality British researchers have developed biomaterials that better recreate the conditions required for stem cells to grow into desired cell types. Researchers at Imperial College London have used 3D printing to create biological structures that can support tissue regeneration. The study, published in Scientific Reports, outlines how the group used cryogenics – freezing – to create a biomaterial that mimics the […] January 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2018 Here’s Another Reason to Eat Plenty of Fruit and Vegetables Researchers have discovered that bacteria break down fruit and vegetables to produce chemicals that control our genes and could help to prevent cancer and fight infections. British scientists from the Babraham Institute in Cambridge, UK, with colleagues from Brazil and Italy, have discovered a mechanism by which helpful bacteria in the gut can control the […] January 11, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Scancell and BioNTech Will Combine Their Expertise to Fight Cancer Scancell has brought in BioNTech to develop T-cell receptors against specific target proteins in cancer cells, opening the door to new cancer treatments that target them. Scancell works on immunotherapies for the treatment of cancer and it has announced that it will come together with Europe’s largest private biopharma, BioNTech, to develop T-cell receptor (TCR)-based therapies. […] January 9, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email